Tune Therapeutics
PrivateLast Round
Series B
Jan 12, 2025
Est. Valuation
$339.8M
Total Funding Raised
$223.35M
Company Overview
Tune Therapeutics is a biotechnology company that develops an epigenetic programming platform aimed at creating innovative cell and gene therapies for the treatment of complex diseases by reprogramming biology through the epigenome without modifying the DNA sequence.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tune Therapeutics Comparables
Compare Tune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Moonwalk Biosciences | 89% | |
| Epicrispr Biotechnologies | 88% | |
| Epigenic Therapeutics | 88% | |
Tune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 12, 2025 | ||||
| Series A | Dec 2, 2021 |
Key People
Founding team and executive leadership
Tune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| A. M. Pappas & Associates | Series B |
| New Enterprise Associates (NEA) | Series A, Series B |
| Duke Capital Partners | Series A, Series B |
| WRF Capital | Series B |
| Hatteras Venture Partners | Series A |
| Hevolution Foundation | Series B |
| Yosemite | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2025
Dr. John McHutchison appointed as new Chief Executive Officer.
- Jan 22, 2025
Attended and showcased advancements at the JPM 2025 conference.
Tune Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Tune Therapeutics's valuation, stock price, and market status.